Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a dihydropyridine calcium channel blocker presented as an oral tablet for oral use. It is employed to prevent cerebral vasospasm after subarachnoid hemorrhage and to improve cerebral blood flow in adult patients at risk of cerebral ischemia.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled manufacturing and reliable distribution across global markets.

Nimotop acts as a cerebral vasodilator and is used in conditions affecting cerebral blood flow. - Subarachnoid hemorrhage: reduces the risk of cerebral vasospasm following hemorrhage. - Cerebral ischemia: improves cerebral perfusion in patients with reduced blood flow. - Delayed cerebral ischemia: helps prevent secondary ischemic injury after aneurysmal bleed.

Nimotop may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Dizziness or light‑headedness: often related to blood pressure changes. - Nausea: occasional gastrointestinal upset. - Peripheral edema: mild swelling of the lower limbs. - Hypotension: modest reduction in blood pressure.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare cardiac events. - Allergic reaction: rash, itching, or anaphylaxis. - Liver dysfunction: abnormal liver enzymes. - Severe bradycardia: markedly slow heart rate.

Before initiating Nimotop, consider the following safety measures. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution; assess liver enzymes regularly. - Hypotension: observe blood pressure, especially during dose titration. - Concomitant nitrates: avoid additive vasodilatory effects that may cause profound hypotension. - Pregnancy and lactation: risk unknown; avoid unless clearly justified. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nimotop can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Concomitant nitrates: risk of severe hypotension. - Beta‑blockers: additive cardiovascular depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase nimodipine plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce drug effectiveness. - Diuretics: can enhance hypotensive effect. - Other antihypertensives: monitor blood pressure for additive lowering.